Maverick Capital Ltd. Increases Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Maverick Capital Ltd. boosted its stake in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 12.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,854,488 shares of the company’s stock after purchasing an additional 210,764 shares during the period. Maverick Capital Ltd.’s holdings in Centessa Pharmaceuticals were worth $73,660,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Avoro Capital Advisors LLC lifted its position in Centessa Pharmaceuticals by 34.7% during the 4th quarter. Avoro Capital Advisors LLC now owns 14,555,555 shares of the company’s stock worth $364,034,000 after acquiring an additional 3,747,475 shares in the last quarter. EcoR1 Capital LLC lifted its position in shares of Centessa Pharmaceuticals by 466.4% during the fourth quarter. EcoR1 Capital LLC now owns 3,115,000 shares of the company’s stock worth $77,906,000 after purchasing an additional 2,565,000 shares in the last quarter. Braidwell LP purchased a new position in shares of Centessa Pharmaceuticals in the fourth quarter valued at $54,730,000. Adage Capital Partners GP L.L.C. grew its holdings in Centessa Pharmaceuticals by 20.8% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,403,000 shares of the company’s stock valued at $110,415,000 after purchasing an additional 1,449,000 shares in the last quarter. Finally, Balyasny Asset Management L.P. acquired a new stake in Centessa Pharmaceuticals during the 2nd quarter valued at $16,052,000. 82.01% of the stock is owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Price Performance

NASDAQ CNTA opened at $40.50 on Tuesday. Centessa Pharmaceuticals PLC Sponsored ADR has a 52 week low of $12.74 and a 52 week high of $40.56. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.23. The stock has a market cap of $6.27 billion, a price-to-earnings ratio of -22.63 and a beta of 1.11. The company has a 50-day moving average price of $40.16 and a two-hundred day moving average price of $33.89.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). Analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current year.

Analyst Upgrades and Downgrades

CNTA has been the topic of a number of analyst reports. B. Riley Financial lowered Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Wells Fargo & Company cut shares of Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and upped their price target for the company from $35.00 to $42.00 in a report on Monday, April 20th. Lifesci Capital lowered shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Monday, April 20th. Finally, Truist Financial downgraded Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 price target for the company. in a research note on Monday, April 13th. Four equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $41.33.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.